Publications by authors named "Fumiya Wada"
Article Synopsis
- The study compares outcomes of unrelated cord blood transplantation (UCBT) and haploidentical transplantation with posttransplant cyclophosphamide (PTCy-haplo) in patients without a matched donor, focusing on the impact of CD34 cell counts in cord blood.
- Data from 2014 to 2020 was analyzed, categorizing UCBT cases into those with high (≥0.84 × 10/kg) and low (<0.84 × 10/kg) CD34 cell counts, revealing better neutrophil engraftment in PTCy-haplo compared to both UCB groups.
- While UCB-H showed similar nonrelapse mortality (NRM) and overall survival
Background: The tumour microenvironment (TME), which is modulated after immune-chemotherapy, is involved in tumour growth and metastasis. Programmed cell death 1 (PD-1) expressed on tumour-infiltrating non-malignant cells plays an important role in the TME through the PD-1/programmed cell death ligand 1 (PD-L1) signalling pathway. However, its impact in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- Haploidentical donor transplantation using posttransplant cyclophosphamide (PTCy) and cord blood transplantation (CBT) are effective alternatives when matched donor options are not available for patients with blood cancers.
- The study analyzed 914 patients and found that mild acute graft-versus-host disease (GVHD) improved overall survival after PTCy-haplo and CBT but did not have the same benefit for matched donor transplants.
- Additionally, while limited chronic GVHD positively impacted outcomes after CBT and matched donor transplants, it did not show the same effect after PTCy-haplo, highlighting that the impact of GVHD varies depending on the type of transplant.
Acute kidney injury (AKI) is one of the major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The use of multiple antimicrobials is one of the major causes of post-transplantation AKI, owing to the potential nephrotoxicity of each agent and of drug-drug interactions (DDIs). No satisfactory reports on DDIs the field of allo-HSCT have been published.
View Article and Find Full Text PDFAutoimmune neutropenia (AIN) is an exceptionally rare condition that occurs after liver transplantation. Here, we report an adult case of refractory AIN 3.5 years after liver transplantation.
View Article and Find Full Text PDFThe combination of calcineurin inhibitors and short-term methotrexate has been used as a standard graft-versus-host-disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation. Mini-dose methotrexate (mini-MTX), consisting of 5 mg/m/d on days 1, 3, 6, and 11, is occasionally selected as an alternative considering toxicity. The significance of day 11 administration remains unclear.
View Article and Find Full Text PDFPrediction of responses to chimeric antigen receptor (CAR)-T cell therapies is essential to maximize their therapeutic efficacy for diffuse large B-cell lymphoma (DLBCL). While several tumor-intrinsic risk factors of resistance and/or early relapse have been identified, clinically useful markers that determine potential activity of CAR-T cells have not been fully investigated. T-cell property at the time of leukapheresis may serve as such a marker.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the effectiveness of unrelated cord blood transplantation (CBT) versus HLA 1-3 mismatched related donor peripheral blood stem cell transplantation (PBSCT) in patients lacking HLA-matched donors, involving 7,861 patients with hematologic malignancies.
- Results showed CBT-no ATG led to significantly better overall survival compared to PBSCT-ATG, except for PBSCT-ATG patients with an HLA 1 mismatch, who had comparable survival rates.
- CBT-no ATG also exhibited lower rates of severe graft-versus-host disease and nonrelapse mortality, although it had delayed neutrophil and platelet engraftment compared to PBSCT-ATG.
Background: Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) have become alternative options to treat patients with hematological malignancies without a HLA-matched donor.
Methods: We conducted a retrospective study using registry data from the Kyoto Stem Cell Transplantation Group for patients with hematological malignancies who received their first allogeneic hematopoietic cell transplantation using a single UCB unit (n = 460) or PTCy-haplo (N = 57) between 2013 and 2019.
Results: We found that overall survival in the UCB group was comparable to that in the PTCy-haplo group (hazard ratio, 1.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of diseases with variable outcomes. Although several prognostic markers have been developed, specific biomarkers for stratifying treatment strategies have not been fully investigated. This study aimed to analyze the clinical impact of the expression of cluster of differentiation (CD) 38, which is associated with cellular proliferation and disease progression, in patients with de-novo DLBCL.
View Article and Find Full Text PDFThe donor selection algorithm for cord blood (CB) with regards to matched related and unrelated donors has not been fully investigated. To assess the potential of CB transplantation (CBT) in patients with hematologic malignancies, especially for high-risk patients, we performed a single-institute retrospective analysis and compared the clinical outcomes of CBT with those of HLA-matched sibling and unrelated donor transplantation. We included 394 patients aged 16 years and older with hematologic diseases who received their first allogeneic hematopoietic cell transplantation between 1990 and 2018 at Kyoto University Hospital.
View Article and Find Full Text PDFArticle Synopsis
- Autologous stem cell transplantation (ASCT) can be treated with high doses of thiotepa and busulfan, specifically for patients with CNS lymphoma.
- In a study, three out of 24 patients experienced secondary failure of platelet recovery (SFPR) about 38 days post-treatment, despite normal initial platelet levels and blood cell recovery.
- This adverse effect was not observed in a larger group receiving a different conditioning regimen, suggesting that busulfan-based treatments may increase the risk of SFPR, highlighting the need for careful monitoring.